ArticleEuropean archives of psychiatry and clinical neuroscience2026
Associations between plasma BDNF, VEGF, and EGF and cognition in drug-naïve schizophrenia with and without sleep disturbances.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCognitive impairment is core symptom in schizophrenia (SCZ), and sleep disturbances (SD) are common and linked to worse cognition. The roles of plasma brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) in drug-naïve SCZ, particularly across SD strata, remain unclear.
methodsWe enrolled 138 drug-naïve patients with SCZ at Tianjin Anding Hospital and stratified them by Pittsburgh Sleep Quality Index (PSQI) into the sleep disturbance group (SCZ-SD) (n = 81) and the non-sleep disturbance group (SCZ-NSD) (n = 57). Cognition was assessed with the MATRICS Consensus Cognitive Battery (MCCB). Plasma BDNF, VEGF, and EGF were quantified by enzyme-linked immunosorbent assay (ELISA). Group comparisons, partial correlations, receiver operating characteristic (ROC) analyses, and sensitivity analyses were conducted.
resultsSCZ-SD patients showed more severe cognitive impairment than SCZ-NSD, particularly in Verbal Learning, Visual Learning, and composite scores (P < 0.05). In SCZ-SD, BDNF was positively correlated with multiple cognitive domains (FDR-adjusted P < 0.05) and showed modest discriminative ability for cognitive impairment with an area under the curve (AUC) of 0.648. In SCZ-NSD, EGF showed a nominal, exploratory association with use of sleep medication (uncorrected P < 0.05), and the combined plasma-marker model demonstrated fair discrimination of cognitive impairment (AUC = 0.694).
conclusionsSCZ-SD patients showed more severe cognitive impairment, and higher BDNF was robustly associated with better cognitive performance. In contrast, SCZ-NSD patients showed associations between EGF and sleep-related measures. These findings suggest distinct biological pathways linking sleep and cognition in SCZ with and without SD, though their current discriminative accuracy suggests an adjunctive rather than standalone diagnostic role.
Indexed as
Identifiers
42215707What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.